3 recruiting, 2 terminated, 2 withdrawn, 1 active not recruiting. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 3, Terminated 2, Withdrawn 2, Active not recruiting 1, Completed 1 |
Follow LN-145: new trials by email Literature Review of LN-145 trials Research Report on LN-145
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma Lifileucel - Sarcoma, Soft Tissue Sarcoma (STS) | Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 80 | 2026-10-02 | 2026-10-09 |
| TIL Therapy in cSCC and MCC LN-145, Cyclophosphamide, Fludarabine - Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Karam Khaddour, MD, MS | 14 | 2026-02-10 | 2026-02-13 |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer LN-145 - Metastatic Non Small Cell Lung Cancer | Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 170 | 2021-05-07 | 2026-06-26 |
| Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy Cyclophosphamide, Fludarabine, Fludarabine Phosphate - Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2019-06-20 | 2020-01-02 | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Lifileucel, LN-145, Pembrolizumab - Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Terminated | Iovance Biotherapeutics, Inc. | 225 | 2019-05-07 | 2026-05-15 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2018-04-27 | 2026-05-22 |
| Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer LN-145, Durvalumab - Non Small Cell Lung Cancer | Phase 2 | Withdrawn | Iovance Biotherapeutics, Inc. | 2018-02-28 | 2019-04-16 | |
| Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma LN-145, LN-145 + pembrolizumab - Cervical Carcinoma | Phase 2 | Terminated | Iovance Biotherapeutics, Inc. | 210 | 2017-06-22 | 2026-09-25 |
| Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck LN-145, LN-145-S1 - Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Completed | Iovance Biotherapeutics, Inc. | 64 | 2017-01-09 | 2023-10-12 |
Carcinoma, Non-Small-Cell Lung (3) · Histiocytoma, Malignant Fibrous (2) · Sarcoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Bone Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Merkel Cell (1) · Giant Cell Tumor of Bone (1) · Liposarcoma (1) · Lung Diseases (1) · Lung Neoplasms (1) · Melanoma (1) · Osteosarcoma (1) · Ovarian Neoplasms (1)
Iovance Biotherapeutics, Inc. (6) · Karam Khaddour, MD, MS (1) · M.D. Anderson Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (9) · Germany (3) · Spain (3) · Switzerland (3) · United Kingdom (3) · Canada (2) · France (2) · Italy (2) · Netherlands (2) · Australia (1) · Greece (1) · Singapore (1) · South Korea (1)
Amir A Jazaeri (1) · Gurkamal Chatta, MD (1) · Karam Khaddour, MD (1)
2016 (1), 2018 (1), P30CA016056 (1)